Skip to main content

Advertisement

SpringerLink
Log in

Sustained Complete Remission of Metastatic Hepatocellular Carcinoma with Single Agent Sorafenib

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.

    Article  PubMed  Google Scholar 

  3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

    Article  PubMed  CAS  Google Scholar 

  4. So BJ, Bekaii-Saab T, Bloomston MA, Patel T. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. J Hematol Oncol. 2008;1:18.

    Article  PubMed  Google Scholar 

  5. Wang SX, Byrnes A, Verma S, Pancoast JR, Rixe O. Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. Target Oncol. 2010;5(1):59–63. Epub 2010 Mar 23.

    Article  PubMed  Google Scholar 

  6. Sacco R, Bargellini I, Gianluigi G, Bertini M, Bozzi E, Altomare E, Battaglia V, Romano A, Bertoni M, Capria A, Bresci G, Bartolozzi C. Complete response for advanced liver cancer during sorafenib therapy: case Report. BMC Gastroenterol. 2011;11:4.

    Article  PubMed  CAS  Google Scholar 

  7. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Su Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. Epub 2008 Dec 16.

    Article  PubMed  CAS  Google Scholar 

  8. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrumoral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–109.

    Article  PubMed  CAS  Google Scholar 

  9. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851–8.

    Article  PubMed  CAS  Google Scholar 

  10. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293–300.

    Article  PubMed  CAS  Google Scholar 

  11. Huitzel-Melendez FD, Saltz LB, Song J et al (2007) Retrospective analysis of outcome in hepatocellular carcinoma (HCC) patients with hepatitis C (C+) versus B (B+) treated with sorafenib (abstract). In 2007 ASCO Gastrointestinal Cancers Symposium, January 19–21, 2007, Orlando, FL: (abstract 173).

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Baylor College of Medicine, 1709 Dryden Road, Houston, TX, 77004, USA

    Premal D. Lulla, Jonathan E. Brammer, Salman Bandeali & Garret R. Lynch

Authors
  1. Premal D. Lulla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan E. Brammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salman Bandeali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Garret R. Lynch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan E. Brammer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lulla, P.D., Brammer, J.E., Bandeali, S. et al. Sustained Complete Remission of Metastatic Hepatocellular Carcinoma with Single Agent Sorafenib. J Gastrointest Canc 44, 98–101 (2013). https://doi.org/10.1007/s12029-012-9438-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-012-9438-6

Keywords

Search

Navigation